Department of Laboratory, Ninth Forty Hospital of the Chinese People's Liberation Army Joint Security Force, Lanzhou 730050, Gansu, China; School of Public Health, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, Gansu, China.
School of Public Health, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, Gansu, China.
J Diabetes Complications. 2023 Sep;37(9):108565. doi: 10.1016/j.jdiacomp.2023.108565. Epub 2023 Jul 28.
Protein kinase C (PKC) is a family of serine/threonine protein kinases that play an important role in many organs and systems and whose activation contributes significantly to endothelial dysfunction in diabetes. The increase in diacylglycerol (DAG) under high glucose conditions mediates PKC activation and synthesis, which stimulates oxidative stress and inflammation, resulting in impaired endothelial cell function. This article reviews the contribution of PKC to the development of diabetes-related endothelial dysfunction and summarizes the drugs that inhibit PKC activation, with the aim of exploring therapeutic modalities that may alleviate endothelial dysfunction in diabetic patients.
蛋白激酶 C（PKC）是一族丝氨酸/苏氨酸蛋白激酶，在许多器官和系统中发挥重要作用，其激活对糖尿病中的内皮功能障碍有重要贡献。高葡萄糖条件下二酰基甘油（DAG）的增加介导 PKC 的激活和合成，刺激氧化应激和炎症，导致内皮细胞功能受损。本文综述了 PKC 对糖尿病相关内皮功能障碍发展的贡献，并总结了抑制 PKC 激活的药物，旨在探索可能缓解糖尿病患者内皮功能障碍的治疗方法。
